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a b s t r a c t
Respiratory syncytial virus (RSV)-induced bronchiolitis in infants is not responsive to glucocorticoids.
We have shown that RSV infection impairs glucocorticoid receptor (GR) function. In this study, we have
investigated the mechanism by which RSV impairs GR function. We have shown that RSV repression of
GR-induced transactivation is not mediated through a soluble autocrine factor. Knock-down of
mitochondrial antiviral signaling protein (MAVS), but not retinoic acid-inducible gene 1 (RIG-I) or
myeloid differentiation primary response gene 88 (MyD88), impairs GR-mediated gene activation even in
mock-infected cells. Over-expression of the RSV nonstructural protein NS1, but not NS2, impairs
glucocorticoid-induced transactivation and viruses deleted in NS1 and/or NS2 are unable to repress
glucocorticoid-induction of the known GR regulated gene glucocorticoid-inducible leucine zipper (GILZ).
These data suggest that the RSV nonstructural proteins mediate RSV repression of GR-induced
transactivation and that inhibition of the nonstructural proteins may be a viable target for therapy
against RSV-related disease.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Respiratory syncytial virus (RSV) is the major cause of severe lower
respiratory tract infections in children, resulting in 132,000–172,000
infant hospitalizations/year in the USA (Stockman et al., 2012).
Although most children survive in the developed world, there is a
signiﬁcant economic burden associated with RSV disease. Treatment of
severe RSV symptoms in children is estimated to cost $600 billion
annually in the USA (Paramore et al., 2004). In addition to children,
immunocompromised adults and the elderly are also at risk from
severe RSV disease (Falsey and Walsh, 2005; Raboni et al., 2003).
RSV is a single-strand negative-sense RNA pneumovirus of the
Paramyxoviridae family that causes bronchiolitis, an inﬂammatory
disease of the bronchioles. Glucocorticoids, one of the most
powerful anti-inﬂammatory agents available, have no beneﬁcial
effect for infants with RSV-induced bronchiolitis (Buckingham
et al., 2002; Bulow et al., 1999; Cade et al., 2000; Ermers et al.,
2009; Loppow et al., 2001; Panickar et al., 2009; Richter and
Seddon, 1998; Roosevelt et al., 1996; Somers et al., 2009).
In addition, glucocorticoids show impaired suppression of RSV-
induced cytokines in vitro (Bonville et al., 2001; Carpenter et al.,
2002; Hinzey et al., 2011). These data suggest that RSV may have a
deleterious effect on glucocorticoid signaling. In fact, we have
recently shown that RSV infection represses glucocorticoid recep-
tor (GR)-mediated gene activation (Hinzey et al., 2011).
Viral infection could interfere with host GR signaling by three
potential pathways: production of autocrine factors such as
cytokines; activation of other host signaling pathways; or through
a direct effect of the viral proteins or RNA. RSV infection of lung
epithelial cells results in the production and release of a number of
cytokines and in the activation of several intracellular signaling
pathways (Garofalo et al., 1996; Lindemans et al., 2006;
Mastronarde et al., 1996; Singh et al., 2007; Thomas et al., 2002).
In this study we investigated which of these mechanisms RSV
utilizes to impair GR function. We show that the RSV nonstructural
proteins mediate these repressive actions of RSV infection on GR
function through inhibition of mitochrondrial antiviral signaling
protein (MAVS).
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Results
Effect of soluble secreted factors on GR-mediated transactivation
RSV induces the expression of soluble cytokines, and cytokines
have been shown to play a role in glucocorticoid insensitivity
(Hu et al., 2009; Irusen et al., 2002; Ishiguro, 1999; Leung et al.,
1995; Matthews et al., 2004; Pace et al., 2011; Sher et al., 1994;
Tliba et al., 2008). Therefore, we tested the effect of conditioned
media produced from RSV- or mock-infected A549 cells on the
ability of dexamethasone to induce a known GR-regulated gene.
Analysis of the conditioned media from RSV-infected cells showed
increased levels of 27 cytokines, including RANTES, interleukin 6
(IL-6), IL-8 and IL-1α that were not present in conditioned media
from mock-infected cells (data not shown). Conditioned media
from RSV-infected cells, which also contains live virus, was either
applied directly to uninfected cells or UV-irradiated, to inactivate
live virus, prior to addition to the uninfected cells. Both of these
treatments increased the expression of IL-8 mRNA whereas con-
ditioned media from mock-infected cells did not (Fig. 1A). Dex-
amethasone induction of GILZ (Fig. 1B) or mitogen-activated
protein (MAP) kinase phosphatase 1 (MKP-1) (Fig. 1C) was similar
in cells treated with conditioned media from mock-infected cells
or from RSV-infected cells, either untreated or UV-irradiated.
Role of intracellular signaling pathways in RSV suppression
of GR-mediated transactivation
RSV is known to activate a number of intracellular signaling
pathways (Garofalo et al., 1996; Lindemans et al., 2006;
Mastronarde et al., 1996; Singh et al., 2007; Thomas et al., 2002),
therefore, the role of these pathways in RSV-mediated suppression
of glucocorticoid induction of a GR-regulated gene was investi-
gated. Speciﬁcally, RSV is known to stimulate the Toll-like receptor
(TLR) and RIG-like helicase (RLR) pathways (Haeberle et al., 2002;
Kurt-Jones et al., 2000; Liu et al., 2007, 2008; Lukacs et al., 2010;
Murawski et al., 2009; Segovia et al., 2012). MyD88, the common
adaptor molecule of the Toll-like receptors (TLRs), and RIG-I were
knocked down by siRNA. RSV infection of A549 cells transfected
with siRNAs against MyD88, RIG-I or a control siRNA repressed
dexamethasone induction of GILZ to similar levels compared to
mock-infected cells (Fig. 2A). Dexamethasone induction of GILZ
was slightly higher in mock-infected cells transfected with RIG-I
siRNA compared to control siRNA. Knock-down of individual gene
expression was conﬁrmed by real-time PCR (Fig. 2B and C).
Knock-down of MAVS, the common adaptor of the RIG-I-like
receptors (RLR), reduced dexamethasone induction of GILZ in
mock-infected cells compared to control siRNA (Fig. 3A). Gluco-
corticoid induction of GILZ in cells transfected with MAVS siRNA
was further reduced by RSV infection, though this slight effect was
not statistically signiﬁcant. As above, efﬁciency of siRNA knock-
down was conﬁrmed by real-time PCR (Fig. 3B).
Effect of the RSV nonstructural proteins on GR-mediated
transactivation
The RSV nonstructural proteins have been shown to inhibit
interferon induction by direct interaction with components of the
RLR pathway (Boyapalle et al., 2012; Ling et al., 2009), Since siRNA
knock-down of MAVS abrogated RSV-mediated inhibition of GR-
induced GILZ expression, we tested whether the RSV NS proteins
were responsible for the effect of RSV on GR-mediated transactivation.
Over-expression of either HA- (Fig. 4A) or FLAG-tagged (Fig. 4B) NS1
repressed dexamethasone induction of the glucocorticoid-responsive
promoter MMTVLuc when expressed by transient transfection in Cos7
cells. Over-expression of NS2 or the empty vector had no effect of
dexamethasone-induced MMTVLuc activity. Co-expression of NS1 and
NS2 repressed dexamethasone-induced MMTVLuc activity similarly to
NS1 alone. Expression was conﬁrmed by western blotting using
antibodies directed against the HA- or FLAG-tags (Fig. 4C and D).
The HA-tagged NS1was not detected by the HA-tag antibody although
there is clearly an effect of transfection of this construct.
To conﬁrm this effect in the context of viral infection, we
infected A549 cells with either wild-type recombinant RSV (rA2)
or recombinant RSV that lack NS1 (ΔNS1e), NS2 (ΔNS2e), or both
NS1 and NS2 (ΔNS1/2e). These recombinant viruses contain GFP
inserted in place of the deleted genes. Infection of A549 cells with
wild-type rA2 virus repressed dexamethasone-induced GILZ
whereas infection with RSV lacking NS1 (ΔNS1e and ΔNS1/2e)
had no effect of glucocorticoid-induced GILZ (Fig. 5). Unexpectedly,
Fig. 1. RSV repression of GR-induced genes is not mediated by a soluble secreted
factor. Conditioned media from mock-infected cells (CM) (open bar), RSV-infected
cells (RSV CM) (solid bar) or UV-irradiated conditioned media from RSV-infected
cells (UV-RSV CM) (hatched bar) was added to uninfected A549 cells. After 5 h
vehicle or dexamethasone was added such that the ﬁnal concentration was 100 nM
and cells were incubated for a further 5 h. A. IL-8 mRNA was detected in vehicle
only treated cells by real-time PCR, normalized to GAPDH and CAP-1 and compared
to untreated cells. Dexamethasone-induced GILZ (B) and MKP-1 (C) mRNA was
determined by real-time PCR and normalized to GAPDH and CAP-1. Means and SD
are shown (n¼5). Signiﬁcance was tested using a 1-way ANOVA and Dunnett post
hoc test (nnndepicts po0.001).
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infection with ΔNS2e also did not inhibit GILZ expression after
dexamethasone treatment. Real-time PCR conﬁrmed the expected
expression patterns of the NS genes in cells infected with rA2 or
the NS-deletion recombinant RSVs. In addition, viral genome
levels were not affected by 5 h dexamethasone treatment and
were relatively similar among the cells infected by the NS-deletion
and wild type rRSV, indicating equal input infection and a lack of
effect of dexamethasone on RSV infection (data not shown).
To examine transcription, we determined F mRNA levels, since
F is downstream of the NS genes and should be less affected by
changes in the transcription gradient due to NS gene alteration
than genes that are more promoter-proximal. We found that F RNA
levels were unaffected by dexamethasone treatment, similar to the
viral genome levels, and expressed to comparable levels in rA2-,
ΔNS1, and ΔNS1/2-infected cells (data not shown). However,
F RNA was present at higher levels in ΔNS2-infected cells, though
this expression did not appear to affect GR activation.
Discussion
We previously showed that RSV infection represses glucocorticoid-
induced gene expression (Hinzey et al., 2011). In this study, we
examined the mechanisms by which RSV accomplishes this effect.
RSV infection could impair GR function by three potential mechan-
isms: by production of secreted autocrine factors; by activation of
intracellular signaling pathways; or by a direct protein/RNA effect.
RSV-infected lung epithelial cells produce a number of cytokines. IL-1α
has been previously shown to function in an autocrine fashion to
mediate RSV-induction of IL-6, IL-8 and intracellular adhesion mole-
cule 1 (ICAM-1) (Jiang et al., 1998; Patel et al., 1998, 1995). IL-10 acts in
an autocrine manner to reduce inﬂammation by inhibiting T-cell
responses (Loebbermann et al., 2012; Sun et al., 2011). The role of
cytokines in glucocorticoid insensitivity/resistance has been previously
described. Cytokines, such as IL-2/IL-4, IL-13 tumor necrosis factor α
(TNFα), IL-6, IL-8, interferon γ (IFNγ) and IFNα have been shown to
impair GR function and are proposed to be involved in glucocorticoid
resistance/insensitivity in diseases such as asthma, ulcerative colitis,
and depression (Hu et al., 2009; Irusen et al., 2002; Ishiguro, 1999;
Leung et al., 1995; Matthews et al., 2004; Pace et al., 2011; Sher et al.,
1994; Tliba et al., 2008). Thus, the hypothesis that RSV-induced
cytokines could impair GR function was tested. We have shown that
RSV-conditioned media-induced IL-8 transcription as previously
described (Patel et al., 1998). However, this RSV-conditioned media
did not reduce glucocorticoid induction of the known GR-regulated
genes GILZ and MKP-1 (Fig. 1), suggesting that the repression of GR
function by RSV infection is not mediated by a soluble autocrine factor.
RSV infection activates a number of intracellular signaling
pathways, including Nuclear factor κ B (NFκB), phosphoinositide
3-kinase (PI3K), and MAP kinase pathways (Garofalo et al., 1996;
Lindemans et al., 2006; Mastronarde et al., 1996; Singh et al., 2007;
Thomas et al., 2002). Activation of such pathways could result in
glucocorticoid insensitivity/resistance as GR is known to cross-talk
with and mutually antagonize these pathways (Adcock and Lane,
2003; Ayroldi et al., 2012; Irusen et al., 2002; Marwick et al., 2009;
Ray and Prefontaine, 1994). In our earlier work, we showed that
RSV repression of GR function was not mediated though the NFκB
pathway (Hinzey et al., 2011). In order to investigate this further
we inhibited the activation of multiple signaling pathways by
interfering with the initiation of these signaling cascades. RSV is
sensed through pathogen recognition receptors in the TLR
(Haeberle et al., 2002; Kurt-Jones et al., 2000; Lukacs et al.,
2010; Murawski et al., 2009; Segovia et al., 2012) and RLR path-
ways (Liu et al., 2007, 2008), resulting in the activation of type I
interferon responses. SiRNA knock-down of MyD88, the common
adapter of the TLR pathways, or RIG-I did not impair RSV
Fig. 2. Knock-down of MyD88 or RIG-I does not reverse RSV repression of dexamethasone-induced GILZ mRNA. A549 cells were transfected with control siRNA or siRNA
against MyD88 or RIG-I. 48 h later they were inoculated with rgRSV (MOI¼3) (solid bar) or mock-infected with HeLa-conditioned media (open bar) for 1 h. The media was
aspirated and cells treated with vehicle or 100 nM dexamethasone for 5 h. Dexamethasone-induced GILZ mRNAwas determined by real-time PCR and normalized to GAPDH
and CAP-1 (A). siRNA knockdownwas conﬁrmed by real-time PCR (B & C). Means and SD are shown (n¼3). Signiﬁcance was tested using a 1-way ANOVA and Tukey post hoc
test (nndepicts p¼0.01–0.001; nnndepicts po0.001).
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repression of glucocorticoid-induced GILZ mRNA (Fig. 2), suggest-
ing that activation of these receptors does not mediate RSV
repression of GR function. However, we cannot fully rule out
TLR3 as some RSV effects mediated through TLR3 are MyD88
independent (Rudd et al., 2005).
Knock-down of MAVS, the downstream adapter molecule of RIG-I,
repressed glucocorticoid-induction of GILZ even in mock-infected cells
(Fig. 3). In the presence of RSV infection glucocorticoid-induction of
GILZ was further repressed. Even though this was not signiﬁcantly
signiﬁcant we cannot rule out biological signiﬁcance due to the
reduced GILZ induction in the mock-infected cells. RSV expresses
two small nonstructural proteins, NS1 and NS2, that suppress type I
interferon response in part by inhibiting the RIG-I-MAVS interaction
(Boyapalle et al., 2012; Ling et al., 2009). Therefore, we tested if NS1
and NS2 could mediate the effect of RSV on GR function. First, we used
a transient transfection system where we over-expressed HA- or
FLAG-tagged NS1 and/or NS2. In this system, over-expression of NS1,
but not NS2, repressed glucocorticoid induction of the glucocorticoid
responsive MMTVLuc promoter. Co-expression of NS1 and NS2
repressed glucocorticoid-induced MMTVLuc activity similarly to NS1
alone (Fig. 4). To conﬁrm these ﬁndings, we used viruses with
deletions in either the NS1 or NS2 genes or both. Deletion of NS1,
alone or in combination with NS2, prevented RSV suppression of
glucocorticoid-induced GILZ (Fig. 5). Unexpectedly, deletion of NS2
also abrogated the RSV effect on glucocorticoid responsiveness. These
data show that the nonstructural proteins mediate the RSV suppres-
sion of GR function.
It is not entirely clear why only NS1 was able to repress
glucocorticoid-induced MMTVLuc activity in the transient transfection
systemwhereas deletion of either NS1 or NS2 from the virus reversed
the repression of glucocorticoid-induced GILZ. It is possible that this is
an artifact of the transient transfection system. Certainly differences in
subcellular localization of NS1 and NS2 following transient transfec-
tion, compared to infection, have been noted. NS2 is found in the
mitochondria and cytoplasmwhen expressed on its own; NS1 is found
to be in the nucleus and in mitochondria either when expressed alone
or when co-expressed with NS2 (Boyapalle et al., 2012; Swedan et al.,
2011; Tan et al., 2013).
Direct impact of a viral component (protein or RNA) on GR
function is not unknown. The Vpr protein of HIV binds directly to
GR, functioning as a coactivator to up-regulate GR (Kino et al.,
1999, 2002; Sherman et al., 2000). The Poxvirus molluscum
contagiosum (MC) protein MC013L binds and inhibits GR (Chen
et al., 2000) and a noncoding RNA has also been shown to impair
GR function (Kino et al., 2010). Our data suggest that the RSV
nonstructural proteins similarly impair GR function. Further stu-
dies are ongoing to determine if the effects of the nonstructural
proteins are mediated through direct protein-protein interactions
or if they are due to the inhibition of the type I interferon pathway.
Repression of the interferon pathway by glucocorticoids is known
(Diez et al., 2012; Flammer et al., 2010; McCoy et al., 2008) but
there is no literature to suggest that the interferon pathway can
repress GR function. In addition, other viruses, such as pneumonia
virus of mice, Sendai virus, inﬂuenza, dengue virus and Ebola
virus, have proteins similar to the RSV nonstructural proteins that
inhibit the interferon response (Aguirre et al., 2012; Buchholz
et al., 2009; Heinze et al., 2011; Mibayashi et al., 2007; Prins et al.,
2009; Strahle et al., 2007). It has yet to be determined if these
proteins from other viruses also impair GR function.
To date there is no vaccine for RSV and early attempts with a
formalin-inactivated vaccine proved fatal. Interestingly, viruses
deleted in NS1 and/or NS2 are novel candidates for vaccine
development (Wright et al., 2006). Although this is primarily
due to their limited virulence it is possible that the loss of the
glucocorticoid suppressive action may also help in the production
of a useful vaccine. In addition, inhibition of the nonstructural
proteins may be a viable target for therapy against RSV-related
disease. Inhibition of these proteins would not only enhance host
anti-viral interferon responses but would also enhance glucocor-
ticoid responsiveness.
Materials and methods
Materials
Dexamethasone was purchased from Sigma-Aldrich (St. Louis,
MO) and was dissolved in 99.5% ethanol.
Cell culture
A549 cells, an alveolar cell carcinoma derived cell line which
retains features of the type II alveolar epithelial cells, are routinely
used as a model for RSV infection of epithelial cells (Huang et al.,
2008). A549 cells (American Type Culture Collection (ATCC),
Manassas, VA) were grown in DMEM/F12 (50/50) media with
10% fetal bovine serum (FBS) and Cos7 cells (ATCC, Manassas, VA),
were grown in DMEM media with 10% FBS at 37 1C and 5% CO2.
Production of NS deletion recombinant RSV expressing GFP
Recombinant RSV (rRSV) expressing enhanced green ﬂuores-
cent protein (eGFP) were constructed by amplifying eGFP from
pEGFP-C3 (Promega Corp., Madison, WI) by PCR using 5′ primers
containing either an NheI (NS1) or Acc65I (NS2) and 3′ primers
Fig. 3. Knock-down of MAVS reduces glucocorticoid induction of GILZ and
eliminates RSV repression of glucocorticoid-induced GILZ. A549 cells were trans-
fected with control siRNA or siRNA against MAVS. 48 h later they were inoculated
with rgRSV (MOI¼3) (solid bar) or mock-infected with HeLa-conditioned media
(open bar) for 1 h. The media was aspirated and cells treated with vehicle or
100 nM dexamethasone for 5 h. Dexamethasone-induced GILZ mRNA was deter-
mined by real-time PCR and normalized to GAPDH and CAP-1 (A). siRNA knock-
down was conﬁrmed by real-time PCR (B). Means and SD are shown (n¼3).
Signiﬁcance was tested using a 1-way ANOVA and Tukey post hoc test (ndepicts
p¼0.05–0.01;nndepicts p¼0.01–0.001).
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containing either a SpeI (NS1) or BsiWI (NS2) site. These eGFP
fragments were digested with the appropriate enzymes and
inserted into similarly digested pGEM-NSsites (Ling et al., 2008).
Full-length mutant D53 plasmids were produced and recombinant
RSV expressing eGFP in place of NS1 (ΔNS1e), NS2 (ΔNS2e), or
both NS1 and NS2 (ΔNS1/2e) were recovered as described (Tran
et al., 2007).
Virus preparation
Recombinant green ﬂuorescent protein (GFP)-expressing RSV
(rgRSV) was grown in HeLa cells, separated from debris by low
speed centrifugation and further puriﬁed by pelleting in a high
speed centrifuge (Hallak et al., 2000). Speciﬁcally, monolayer HeLa
cells were inoculated with rgRSV for 2 h. Media was removed and
fresh media added. Two days later cells were harvested, virus
detached by vortexing and cells removed by low speed centrifuga-
tion at 1200 rpm for 5 min. Virus was further puriﬁed by high
speed centrifugation at 20,000 g for 1.5 h. Viral pellets were
resuspended in HBSS and snap frozen Mock-infected HeLa-condi-
tioned media was produced by treating the cells in the same
manner but no RSV was used to initially infect the cells. Viral titer
was determined by a ﬂuorescent titration assay as previously
described (Hinzey et al., 2011). Virus stocks of recombinant wild-
type RSV (rA2) and NS-deletion viruses were produced in Vero
cells and titered by plaque assay as described (Tran et al., 2007).
UV-irradiation of RSV
Viral replication was inhibited by UV irradiation. The virus,
rgRSV was diluted in media without FBS, distributed in 800 μl
aliquots in an open 12-well cell culture plate and UV-irradiated at
184 μJ/cm2 for 20 min. Success of UV-irradiation was conﬁrmed by
the failure to detect GFP in cells inoculated with the UV-rgRSV.
Viral infection of A549 cells
For viral adsorption, media was removed from A549 cells and
fresh media without FBS containing RSV at the required multi-
plicity of infection (MOI) was added to the cells for 1 h. The media
was then replaced with fresh media containing 10% serum and
treated as indicated.
Production of RSV conditioned media
A549 cells were inoculated with rgRSV (MOI¼1) or mock-
infected with HeLa-conditioned media for 1 h. The media was
aspirated and fresh media supplied. After 2 days supernatants
were collected from mock-infected cells or RSV-infected cells,
centrifuged at 12,000 g for 5 min and then either applied directly
or after UV-irradiation to uninfected A549 cells.
Transient transfection
Cos7 cells were plated in 24-well cell culture plates in DMEM
containing 10% charcoal stripped serum (CSS) at a concentration of
5104 cells/well. The next day cells were transfected with 20 ng hGR,
100 ng of the GR-responsive promoter, MMTVLuc, 20 ng of the
constitutively active renilla internal control, pRL-TK (Promega Corp.,
Madison, WI), HA- or FLAG-tagged NS1 and/or NS2 or the empty
plasmid SB897 and pSG5 (empty plasmid) using TransIT-LT1 (Mirus
Bio, Madison, WI) according to the manufacturer's instructions. The
following day the cells were treated with vehicle or 100 nM dexa-
methasone for 5 h, the cells were lysed and luciferase measured using
Fig. 4. Over-expression of NS1 represses glucocorticoid-induced MMTVLuc activity. Cos7 cells were transfected with hGR, the GR-responsive MMTVLuc promoter;
a constitutively active control renilla vector, and either a HA-((A) and (C)) or FLAG-tagged ((B) and (D)) NS1 or NS2 expression vector or the empty vector SB897. Cells were
treated with vehicle or 100 nM dexamethasone for 5 h. Fireﬂy luciferase was normalized to renilla luciferase and fold increase following dexamethasone treatment was
calculated. Means and SD are shown (n¼3). Signiﬁcance was tested using a 1-way ANOVA and Dunnett post hoc test. (a); p¼0.05–0.01 when compared to 5 ng SB897: (b);
p¼0.05–0.01 when compared to 10 ng SB897; (c); po0.001 when compared to 5 ng SB897; (d); po0.001 when compared to 10 ng SB897. Cell lysates were taken for
western blotting using antibodies directed against the HA- (C) or FLAG-tags (D). The blots were stripped and re-probed for β-actin. A representative ﬁgure of two repeats
is shown.
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the Dual Luciferase Assay (Promega Corp., Madison, WI) on a Packard
LumiCount luminometer (PerkinElmer, Waltham, MA).
Real-time PCR
Total RNA was extracted using TRIzol (Life technologies, Grand
Island, NY) according to the manufacturer's instructions. 500 ng RNA
was reverse transcribed using the High Capacity cDNA Reverse
Transcription Kit with RNase inhibitor (Life Technologies, Grand
Island, NY) in a 20 μl reaction. cDNA was then diluted by addition
of 100 μl DEPC-treated H2O. Real-time PCR was performed on 8 μl
diluted cDNA in a 20 μl reaction containing 1X Power SYBRs Green
PCR Master Mix (Life technologies, Grand Island, NY) and 0.125 μM of
each primer ((Hinzey et al., 2011) and Table 1) using the following
protocol on an ABI 7300 Real-Time PCR system. Plates were heated at
50 1C for 2 min, denatured for 10 min at 95 1C and subjected to 40
cycles of 95 1C for 15 s and 60 1C for 1 min. Cycle threshold (CT)
values of duplicate samples were analyzed using the comparative CT
(ΔΔCT) method (Life technologies, Grand Island, NY). The fold
induction (2ΔΔCt) by dexamethasone was obtained by normalizing
to the average of two endogenous genes, GAPDH (glyceraldehyde-
3-phosphate dehydrogenase) and CAP-1 (Cyclic AMP-accessory pro-
tein) (Gavrilin et al., 2006), and expressed relative to the amount in
non-treated cells. Relative copy numbers (RCN) were calculated as
2ΔCt100 (Gavrilin et al., 2006).
Western blotting
Total cellular protein was isolated using M-PER in the presence
of protease inhibitors (Thermo Fisher Scientiﬁc Inc., Pittsburgh, PA)
according to the manufacturer's instructions. 10 μg protein was
subjected to SDS-PAGE on NuPAGE Novex 4–12% bis-tris pre-cast
gels (Life Technologies, Grand Island, NY). Proteins were then
transferred to nitrocellulose membranes by semi-dry blotting and
blocked in 5% non-fat dry milk in Tris-buffered saline 0.05%
Tween 20 (TBST). They were then incubated with primary anti-
body raised against the HA-tag (Cell Signaling Technology Inc.,
Danver, MA; 3742; 1:1000) or the FLAG-tag (Cell Signaling Techno-
logy Inc., Danver, MA; 2368; 1:1000) in 5% milk in TBST overnight
at 4 1C. Membranes were then washed three times with TBST and
incubated with goat anti-rabbit IgG-HRP (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA; sc-2004; 1:2000) in TBST for 1 h at room
temperature. Membranes were again washed with TBST and
chemiluminescence detected using SuperSignal West Pico Chemi-
luminscence Substrate (Thermo Fisher Scientiﬁc Inc., Pittsburgh,
PA) according to the manufacturer's instructions and exposed to
autoradiographic ﬁlm. Membranes were stripped for 15 min at
room temperature in Restore Stripping buffer (Thermo Fisher
Scientiﬁc Inc., Pittsburgh, PA) and re-probed using a b-actin
primary antibody (Santa Cruz Biotechnology, Santa Cruz, CA;
sc-47778; 1:2000) and goat anti-mouse IgG-HRP secondary anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA; sc-2005; 1:5000).
siRNA-mediated gene silencing
50 nM siRNA to myeloid differentiation primary response gene 88
(MyD88), retinoic acid-inducible gene 1 (RIG-I), MAVS or control
siRNA-A (Santa Cruz Biotechnology, Santa Cruz, CA; sc-35986,
Fig. 5. RSV deleted in the NS1 and/or NS2 genes does not repress glucocorticoid-
induced GILZ. A549 cells were inoculated with rA2, ΔNS1e, ΔNS2e, ΔNS12e (MOI¼3) or
mock-infected with HeLa-conditioned media for 1 h. The media was changed and cells
were treated with 100 nM dexamethasone for 5 h. Dexamethasone-induced GILZ mRNA
was determined by real-time PCR and normalized to GAPDH and CAP-1 (A). NS1 (open
bar) and NS2 (solid bar) expression was conﬁrmed by real-time PCR (B). Means and SD
are shown (n¼3). Signiﬁcance was tested using a 1-way ANOVA and Dunnett post hoc
test (ndepicts p¼0.05–0.01; nndepicts p¼0.01–0.001).
Table 1
Real-time PCR primers.
Gene name Accession number Direction Primer sequence (5′–3′) Reference
CAP-1 NM_006367.3 F ATTCCCTGGATTGTGAAATAGTC Jiang et al., 1998
R ATTAAAGTCACCGCCTTCTGTAG
GAPDH NM_002046.3 F ACTTTGGTATCGTGGAAGGACT Jiang et al., 1998
R GTAGAGGCAGGGATGATGTTCT
GILZ NM_004089 F GCACAATTTCTCCATCTCCTTCTT Garofalo et al., 1996
R TCAGCATGATTCTTCACCAGATCCA
IL-8 NM_000584.2 F AGTTTTTGAAGAGGGCTGAGAAT Garofalo et al., 1996
R CAACAGACCCACACAATACATGA
MAVS NM_020746.4 F AGACCAGGATCGACTGCGGGC
R AGAGGCCACTTCGTCCGCGA
MKP-1 NM_004417 F CTGCCTTGATCAACGTCTCA Garofalo et al., 1996
R ACCCTTCCTCCAGCATTCTT
MyD88 NM_001172567.1 F GAGCTGGCGGGCATCAC
R TCGAAACGCTCAGGCATATG
RIG-I NM_014314.3 F ACCAGAGCACTTGTGGACGCT
R TGCCGGGAGGGTCATTCCTGT
J.I. Webster Marketon et al. / Virology 449 (2014) 62–69 67
sc-61480, sc-75755 and sc-37007 respectively) was transfected into
A549 cells using DharmaFECT 2 (Thermo Fisher Scientiﬁc Inc.,
Pittsburgh, PA, USA) according to the manufacturer's instructions.
48 h post transfection the cells were inoculated with rgRSV at an
MOI of 3 as described above. After 1 h the inoculumwas removed and
cells treated with vehicle or 100 nM dexamethasone and the expres-
sion of GR-regulated gene, glucocorticoid-inducible leucine zipper
(GILZ), determined by real-time PCR. The efﬁciency of siRNA silencing
was determined by real-time PCR using primers in Table 1.
Statistical analysis
Transfection experiments were performed in triplicate and
real-time experiments in duplicate and the average was treated
as one value. The average values of n independent experiments
were analyzed for statistical signiﬁcance using the two-tailed
unpaired Student's t-test or an ANOVA and appropriate post hoc
test using Prism 5 software (Graphpad Software Inc., La Jolla, CA).
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